JNJ — Demand Zone Reaction + Pharma Pricing News + DividendJohnson & JohnsonNYSE:JNJfadlidaud✅ Chart Analysis 1. Demand Zone Rejection Price pulled back perfectly into a well‑defined demand zone — this is where buyers previously stepped in aggressively. The reaction confirms strong institutional demand. 2. Trendline Break + Retest A descending trendline was broken, and price successfully retested the trendline from above, turning previous resistance into new support. This is a classic continuation signal. 3. EMAs Supporting the Trend Price is trading above the 50‑day EMA, showing short‑term strength. The 200‑day EMA is trending upward, confirming long‑term bullish structure. 4. Volume Behavior During the dip into the demand zone, volume remained controlled — a sign of absorption instead of panic selling. 5. Stochastic Indicator Stochastics curled upward from lower levels, supporting a momentum continuation. 📌 Technical Bias: Bullish as long as price holds above the demand zone ✅ Trade Idea Entry zone: Inside the demand/support area Stop‑loss: Place the stop‑loss below the demand zone, or adjust based on your personal capital allocation and risk tolerance. Take‑profit: Around $255–258, the previous swing structure ✅ Dividend Catalyst (Q2 2026) JNJ is a quarterly dividend stock, paying $1.30 per share as of 2026. According to verified dividend schedules: Next estimated Ex‑Date: May 27, 2026 Next estimated Payment Date: June 10, 2026 ✅ Summary JNJ is showing a clean bullish continuation setup after reacting at a strong demand zone, breaking the descending trendline, and holding above key EMAs. On the fundamentals side, the U.S. administration’s recent agreements with major pharma companies — including JNJ — provide regulatory clarity by introducing MFN drug pricing and tariff exemptions, helping stabilize sector sentiment. With an estimated next ex‑dividend date on May 27, 2026, dividend‑oriented accumulation may offer additional short‑term support. As long as price holds above the demand zone, the bullish outlook toward the $255–258 range remains intact.